In this exclusive Drug Digest video interview, Felicity Thomas, Associate Editorial Director, Pharmaceutical Technology Group, interviews experts about key trends impacting small-molecule APIs and excipients, the importance of supply chain resilience, ways in which advanced manufacturing approaches can prove beneficial, and potential hurdles facing companies seeking to secure their small-molecule API and excipient supply chains.
In this exclusive Drug Digest video interview, Felicity Thomas, Associate Editorial Director, Pharmaceutical Technology Group, interviews experts about small-molecule APIs and excipients. During the first segment of the interview, Kevin Webb, Chief Operating Officer of the API Innovation Center delves into the trends driving change in the small-molecule API space, the importance of supply chain resilience and approaches being used to secure small-molecule API supply chains, the benefits of advanced manufacturing approaches in reshoring, the hurdles facing reshoring efforts, and potential future trends that may impact the small-molecule API space. Next up, Nigel Langley, Global Technical Director, Life Sciences, Gaylord Chemical Company, goes into detail about supply chain security for excipients, the potential impact of using non-compendial materials in a formulation, and some best practices that should be employed to ensure that no adulterated and non-compendial materials enter drug development processes. Additionally, he provides a teaser as to what viewers can look forward to at an upcoming panel discussion, taking place at CPHI in Milan.
Kevin Webb
Kevin Webb is the Chief Operating Officer of the API Innovation Center where he has direct responsibility for business operations, programs, strategy and external engagement. He leads the API Innovation Center’s efforts at a national and regional level to strengthen domestic pharmaceutical manufacturing in the U.S. and is a subject matter expert and featured speaker on the importance of securing our national health security.
Kevin brings 30 years of experience in the healthcare industry with broad, cross-functional technical expertise in government affairs, communications, manufacturing, operations, sales and brand management. He is a highly respected and trusted representative of the pharmaceutical industry.
Prior to the API Innovation Center, Kevin held leadership roles at Mallinckrodt Pharmaceuticals, Sanofi Pasteur Vaccines and Memorial Medical Center, a tertiary health center in Central Illinois. He holds an MBA from the University of Illinois and a Bachelor of Science from St. Louis University.
Nigel Langley
Nigel Langley, Global Technical Director, Life Sciences, Gaylord Chemical Company LLC, provides technical support to the pharmaceutical industry and helps solve drug formulation challenges. Prior to joining Gaylord Chemical Nigel has held various senior technical and marketing positions with BASF and Croda International PLC. Nigel has also worked in Japan and England with Croda. He gained his Chemistry (Hons) degree and PhD (liquid crystals) from the University of Hull (UK) and an MBA from Leeds University (UK). He also took a 2- year Postdoctoral research position at Leeds University (UK) in natural product synthesis. He has over 100 scientific publications and has co- edited 3 books. Nigel is an adjunct professor at the University of Mississippi and a Fellow of the Royal Society of Chemistry (UK). In 2018 he was awarded the Industry Research Achievement Award in Excipient Technology by the IPEC Foundation. He has been a member of the Executive Committee at IPEC- Americas since 2010 and is currently Chair.
This episode of Drug Digest is sponsored by:
Drug Digest is a tech talk video series with the Pharmaceutical Technology® editors, who interview industry experts to discuss the emerging opportunities, obstacles, and advances in the pharmaceutical and biopharmaceutical industry for the research, development, formulation, analysis, upstream and downstream processing, manufacturing, supply chain, and packaging of drug products.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.